ORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES 19413 DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO.-(If-knewn, see 37 CFR 1.5) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/AU2004/000749 4 June 2004 (04.06.2004) 4 June 2003 (04.06.2003) TITLE OF INVENTION METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE GRANULOCITE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT PROCESSES BY MODULATION OF THE LEVELS OF SUPPRESSOR OF CYTOKINE SIGNALING (\$وح\$) APPLICANT(S) FOR DO/EO/US Ben Croker, Andrew Roberts, Don Metcalf, Warren Alexander, Doug Hilton, and Nicos Nicola Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below. \boxtimes 4. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) 5. Ø is attached hereto (required only if not communicated by the International Bureau). b. 🛛 has been communicated by the International Bureau. c. 🗆 is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🔲 is attached hereto. b. 🔲 has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. 8 An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 9. 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. \boxtimes A copy of the International Preliminary Examination Report (PCT/IPEA/409). \boxtimes 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. \boxtimes A FIRST preliminary amendment. 16. A SECOND or SUBSEQUENT preliminary amendment.

A second copy of the published International Application under 35 U.S.C. 154(d)(4).

EV 213901689 US

 \boxtimes

A substitute specification.

Express Mail Label No.

A power of attorney and/or change of address letter.

17

18.

19.

20

21.

22.

A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.

A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).

Approved for use through 3/31/2007. OMB 0651-0021

Under the Paperwork	Reduction Act of 199	35, no pers	ons are required to respond to	U.S. P a col	atent and Tradema ection of information	rk Office; U n unless it	I.S. DEPARTME displays a valid (NT OF COMMERCE			
U.S. APPLICATION NO (if known, see 37 CFR 1.5)			5) INTERNATIONAL	INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER				
	2371	7 +	PCT/AU20	PCT/AU2004/000749			19413				
23. Other items or information: Courtesy Copy of International Application Six (6) Sheets of Drawings Six (6) Sheets of Sequence Listing Assignee: The Walter and Eliza Hall Institute of Medical Research of Parkville, Victoria, Australia											
	g fees have been s					CALCU	JLATIONS	PTO USE			
			•••••	• • • •	***************************************	\$	\$300.00				
If the written opin prepared by IPEA	ation fee (37 CFR ion prepared by IS VUS indicates all c s	\$	\$200.00								
26. Search If the written opin by IPEA/US Search fee (37 C as an International Seal previously of	fee (37 CFR 1.492 ionof the ISA/US of indicates all clain FR 1.445(a)(2)) ha national Searching rch Report prepare communicated to to.	\$	\$400.00								
TOTAI	L OF 24, 25 and	26 =				\$	\$900.00				
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. Total Sheets Extra Sheets Number of each additional 50 or RATE											
	LXII OTTEELS		thereof (round up to a wh		RATE						
- 100 =	0 /50 =		0		x \$250.00	\$	\$0.00				
Surcharge of \$13 declaration after	0.00 for furnishing the date of comme	\$	\$130.00								
CLAIMS	NUMBER F	ILED	NUMBER EXTRA		RATE						
Total claims	* 17	- 20 =	0	X	\$50.00	\$	\$0.00				
Independent clair		- 3=	1	x	\$200.00	\$	\$200.00				
MULTIPLE DEPE	ENDENT CLAIMS	(if applica	able)	+	\$360.00	\$	\$0.00				
TOTAL OF ABOVE CALCULATIONS =						\$	\$1,230.00				
Applicant cla	ims small entity st	tatus. Se	e 37 CFR 1.27. Fees abov	e are	reduced by	\$	\$0.00				
5					UBTOTAL =	\$	\$1,230.00				
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).						\$	\$0.00				
TOTAL NATIONAL FEE =						\$	\$1,230.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$	\$ \$0.00				
TOTAL FEES ENCLOSED =						\$	\$1,230.00				
*Claim calculation based on claims as amended by Preliminary Amendment filed concurrently herewith.						Amoun	it to be	\$			
	1 micrometri		o concurrently	· rer	~~~ CII•	Amous	4 4a ba				

Amount to be

10/559711

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 a. A check in the amount of \$ \$1,230.00 b. Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed. 	to cover the above fees is enclosed. in the amount of \$ to cover the above fees.									
c. The Commissioner is hereby authorized to character to Deposit Account No. <u>19-1013/SSMP</u> .	arge any additional fees which may be required, or credit any overpayment A duplicate copy of this sheet is enclosed.									
information should not be included on this	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.										
SEND ALL CORRESPONDENCE TO:	ALM WHIM									
Leopold Presser	SIGNATURE									
SCULLY, SCOTT, MURPHY & PRESSER	Legpold Presser									
400 Garden City Plaza, Suite 300 Garden City, New York 11530	NAME									
(516) 742-4343	19,827									
	REGISTRATION NUMBER									
	December 5, 2005									
LP/EWG:ej	DATE									

IAP4 Rec'd PCT/PTO 05 DEC 2005

CERTIFICATE OI Applicant(s): Ben Cro	Docket No. 19413										
O Application No. 1	Filing Date Herewith	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned							
Invention: METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE GRANULOCITE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT PROCESSES BY MODULATION OF THE LEVELS OF SUPPRESSOR OF CYTOKINE SIGNALING (SOCS)											
I hereby certify that t	he following corresponde	ence:									
New U.S. Patent App	olication Under 35 U.S.C.	371									
(Identify type of correspondence)											
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37											
CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on											
	December 5, 2005 (Date)		,								
Leopold Presser (Typed or Printed Name of Person Mailing Correspondence)											
(Signature of Person Mailing Correspondence)											
		EV 21390									
·	Note: Each pa	per must have its own certificate of mailing									